Investigation of plasminogen activator inhibitor-1 (PAI-1) levels in patients diagnosed with polycystic ovary syndrome

Authors

DOI:

https://doi.org/10.46328/aejog.v3i1.79

Keywords:

Coagulation, Plasminogen activator inhibitor 1, Polycystic ovary syndrome

Abstract

Objective:The aim of this study was to investigate the plasma levels of plasminogen activator inhibitor -1 (PAI-1) known as a potent inhibitor of fibrinolysis in women with polycystic ovary syndrome (PCOS) and compare with health controls.

Methods: Forty women with PCOS diagnosed using 2003 revised Rotterdam criteria and 40 healthy women who attended to Adnan Menderes University Department of Obstetrics and Gynecology between July-October 2013 were recruited to this prospective study. We noted all participant’s demographic features, calculated body mass index (BMI), waist hip ratio (WHR), and measured blood pressures. We performed modified Ferriman-Gallwey Score (mFGS) and calculated Luteinizing hormone (LH)/Follicle stimulating hormone (FSH) ratio and homeostatic model assessment insulin resistance (HOMA-IR) of participants. PAI-1 levels were measured by using the Human PAI-1 Elisa test. We used the student T test and Mann-Whitney U test as statistical methods. A p-value less than 0.05 was considered statistically significant.

Results: We found PAI-1 levels, fasting insulin levels, HOMA-IR index, BMI significantly higher in the PCOS group compared with the control group. Mean age of the participants was found lower in the PCOS group. Between the groups we found no statistically significant differences in terms of the LH/FSH ratio, fasting glucose, dehydroepiandrosterone and testosterone levels.

Downloads

Published

2021-04-01

How to Cite

1.
Bağlı İhsan, Küçük M. Investigation of plasminogen activator inhibitor-1 (PAI-1) levels in patients diagnosed with polycystic ovary syndrome. Aegean J Obstet Gynecol [Internet]. 2021 Apr. 1 [cited 2021 Apr. 23];3(1):6-9. Available from: https://aejog.com/index.php/aejog/article/view/79